Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.At the Cardiometabolic Health Congress in ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

Medicare has announced the expansion of coverage for Eli Lilly’s Zepbound, a breakthrough drug in the treatment of autoimmune ...

Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...